Bernards R - Search Results

1

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.

Verissimo CS, Overmeer RM, Ponsioen B, Drost J, Mertens S, Verlaan-Klink I, Gerwen BV, van der Ven M, Wetering MV, Egan DA, Bernards R, Clevers H, Bos JL, Snippert HJ. Verissimo CS, et al. Among authors: bernards r. Elife. 2016 Nov 15;5:e18489. doi: 10.7554/eLife.18489. Elife. 2016. PMID: 27845624 Free PMC article.

2

UNC45A confers resistance to histone deacetylase inhibitors and retinoic acid.

Epping MT, Meijer LA, Bos JL, Bernards R. Epping MT, et al. Among authors: bernards r. Mol Cancer Res. 2009 Nov;7(11):1861-70. doi: 10.1158/1541-7786.MCR-09-0187. Epub 2009 Oct 20. Mol Cancer Res. 2009. PMID: 19843631 Free article.

3

TSPYL5 suppresses p53 levels and function by physical interaction with USP7.

Epping MT, Meijer LA, Krijgsman O, Bos JL, Pandolfi PP, Bernards R. Epping MT, et al. Among authors: bernards r. Nat Cell Biol. 2011 Jan;13(1):102-8. doi: 10.1038/ncb2142. Epub 2010 Dec 19. Nat Cell Biol. 2011. PMID: 21170034

4

Identification of F-box only protein 7 as a negative regulator of NF-kappaB signalling.

Kuiken HJ, Egan DA, Laman H, Bernards R, Beijersbergen RL, Dirac AM. Kuiken HJ, et al. Among authors: bernards r. J Cell Mol Med. 2012 Sep;16(9):2140-9. doi: 10.1111/j.1582-4934.2012.01524.x. J Cell Mol Med. 2012. PMID: 22212761 Free PMC article.

5

Finding effective cancer therapies through loss of function genetic screens.

Bernards R. Bernards R. Curr Opin Genet Dev. 2014 Feb;24:23-9. doi: 10.1016/j.gde.2013.11.007. Epub 2013 Dec 20. Curr Opin Genet Dev. 2014. PMID: 24657533 Review.

6

Drug resistance to targeted therapies: déjà vu all over again.

Groenendijk FH, Bernards R. Groenendijk FH, et al. Among authors: bernards r. Mol Oncol. 2014 Sep 12;8(6):1067-83. doi: 10.1016/j.molonc.2014.05.004. Epub 2014 May 21. Mol Oncol. 2014. PMID: 24910388 Free PMC article. Review.

7

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di Nicolantonio F, Bardelli A. Lamba S, et al. Among authors: bernards r. Cell Rep. 2014 Sep 11;8(5):1475-83. doi: 10.1016/j.celrep.2014.07.033. Epub 2014 Sep 4. Cell Rep. 2014. PMID: 25199829 Free article.

8

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.

Huijberts SC, van Geel RM, Bernards R, Beijnen JH, Steeghs N. Huijberts SC, et al. Among authors: bernards r. Future Oncol. 2020 Feb;16(6):161-173. doi: 10.2217/fon-2019-0748. Future Oncol. 2020. PMID: 32027186 Review.

9

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.

Huijberts SCFA, van Geel RMJM, van Brummelen EMJ, Opdam FL, Marchetti S, Steeghs N, Pulleman S, Thijssen B, Rosing H, Monkhorst K, Huitema ADR, Beijnen JH, Bernards R, Schellens JHM. Huijberts SCFA, et al. Among authors: bernards r. Cancer Chemother Pharmacol. 2020 May;85(5):917-930. doi: 10.1007/s00280-020-04066-4. Epub 2020 Apr 9. Cancer Chemother Pharmacol. 2020. PMID: 32274564 Clinical Trial.

10

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.

Jin H, Wang S, Zaal EA, Wang C, Wu H, Bosma A, Jochems F, Isima N, Jin G, Lieftink C, Beijersbergen R, Berkers CR, Qin W, Bernards R. Jin H, et al. Among authors: bernards r. Elife. 2020 Oct 5;9:e56749. doi: 10.7554/eLife.56749. Elife. 2020. PMID: 33016874 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

341 results

Search Page

Filters